Enlitic locks in US$806,000 contract with University of Michigan Health-Sparrow
Enlitic, Inc. (ASX: ENL) has secured a US$806,000 (A$1.15 million) total contract with University of Michigan Health-Sparrow for the migration of approximately 10.6 million radiology and cardiology imaging studies, with the project expected to complete within 12 months. The contract marks the company’s sixth imaging data migration project within the University of Michigan Health system, extending an established institutional relationship to UM Health-Sparrow as the project site.
Beyond the headline contract value, the engagement carries two distinct milestones that signal broader strategic progress: the deployment of Ensight standardisation at significant scale and the first active integration with a Sectra customer.
Michael Sistenich, Managing Director
“This contract with another leading US healthcare provider demonstrates the commercial momentum we are building and the increasing opportunity to combine our migration and Ensight capabilities. Importantly, it also marks our first active integration with a Sectra customer. With approximately 10.6 million studies in scope, this is a significant real-world deployment of our technology at scale.”
When big ASX news breaks, our subscribers know first
Two milestones in one contract: Ensight standardisation and the Sectra integration
This contract delivers two strategically distinct outcomes beyond migration revenue, each representing an investment-relevant milestone in Enlitic’s commercial development.
-
Milestone 1 — Ensight at scale: The project incorporates Ensight standardisation across the historical imaging archive, embedding Enlitic’s data standardisation technology directly into a large-scale healthcare migration. This is not a standalone Ensight sale; it is a combined capability deployment that demonstrates the value of pairing migration expertise with data standardisation at significant scope.
-
Milestone 2 — First Sectra integration: University of Michigan Health-Sparrow will become Enlitic’s first customer to utilise its Sectra integration. The integration enables Ensight’s standardisation results and associated reporting to be incorporated into the university’s Sectra-based imaging environment. Sectra is a publicly traded Swedish medical technology company managing 170 million annual imaging exams and a winner of seven Best in KLAS awards in 2026, making it one of the world’s leading enterprise imaging platforms. This first active integration serves as an important proof point for Ensight’s compatibility with major imaging ecosystems.
The announcement describes the combination of migration and Ensight as a “natural pathway” to introduce Enlitic’s technology into large and complex healthcare environments as customers modernise their imaging infrastructure.
Understanding Enlitic’s migration and data standardisation model
When healthcare systems switch platforms or upgrade their imaging infrastructure, vast archives of studies including MRI, CT scans, X-rays, and ultrasound images must be transferred accurately and without data loss. This process is what Enlitic’s migration services address.
Ensight works alongside these migrations by standardising the data within those archives. Standardisation ensures imaging studies are consistent, usable, and interoperable regardless of which system originally produced them, a meaningful challenge when healthcare organisations consolidate or modernise across multiple legacy platforms.
Migrations are commercially significant for Enlitic because they represent a defined revenue channel with measurable scope (number of studies) and a fixed completion timeline. They also create a direct entry point for Ensight into large healthcare organisations that may later expand its use independently.
The St. Jude Children’s Research Hospital contract, Enlitic’s first engagement in the paediatric sector, also demonstrated how migration projects create a direct entry point for potential Ensight upsell into institutions that would otherwise be difficult to access as first-time customers.
A structural factor underpinning Enlitic’s commercial deployment pathway is its regulatory classification across key markets. Its Class I regulatory classification reflects the low-risk nature of the technology and provides a streamlined pathway for commercial deployment.
| Market | Regulatory Classification | FDA/Equivalent Submission Required |
|---|---|---|
| United States | Class I | No — exempt from FDA premarket submission and approval |
| United Kingdom | Class I | Not specified |
| European Union | Class I | Not specified |
| New Zealand | Class I | Not specified |
| Australia | Class I | Not specified |
The US exemption from premarket submission and approval represents a low-friction commercial deployment pathway, allowing Enlitic to contract with healthcare providers without navigating a lengthy regulatory approval process.
Commercial momentum building across the US healthcare sector
This contract is part of a broader pattern of named, contracted engagements with large-scale US healthcare institutions across CY2026. The following clients represent Enlitic’s significant CY2026 US engagements as disclosed in the announcement:
- Penn Medicine
- St. Jude Children’s Research Hospital
- Parkland Health
- University of Michigan Health-Sparrow (sixth project within the UM Health system)
These are recognised institutions across the US healthcare sector, and the engagements are described as significant CY2026 engagements. Migrations provide not only direct contract revenue but, as the announcement notes, potential opportunities to expand Ensight use across large healthcare organisations following project completion.
The Penn Medicine data migration contract, worth US$1.5 million and covering over 71 million legacy clinical files, established an early template for Enlitic’s combined migration and Ensight deployment model at a recognised US academic health system.
The 12-month completion timeline for the University of Michigan Health-Sparrow contract keeps near-term revenue delivery visible within the current reporting window. With the addition of the first Sectra integration and continued Ensight deployments at scale, the contract adds a further dimension to Enlitic’s CY2026 commercial activity.
Ready to Learn More About Enlitic’s Growing US Healthcare Pipeline?
Enlitic’s US$806,000 contract with University of Michigan Health-Sparrow marks the company’s sixth engagement within the UM Health system and its first active integration with a Sectra customer, covering 10.6 million imaging studies. Combined with contracts at Penn Medicine, St. Jude Children’s Research Hospital, and Parkland Health, the company is building a clear pattern of named, large-scale deployments across recognised US healthcare institutions.
To explore Enlitic’s full suite of imaging migration and data standardisation capabilities, visit the Enlitic investor and product hub for further detail on the company’s commercial progress and technology.